Depomed Company Profile (NASDAQ:DEPO)

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:DEPO
  • CUSIP: 24990810
  • Web:
  • Market Cap: $635.88 million
  • Outstanding Shares: 62,341,000
Average Prices:
  • 50 Day Moving Avg: $11.49
  • 200 Day Moving Avg: $16.05
  • 52 Week Range: $9.50 - $27.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.57
  • P/E Growth: 0.67
Sales & Book Value:
  • Annual Revenue: $441.56 million
  • Price / Sales: 1.44
  • Book Value: $3.69 per share
  • Price / Book: 2.76
  • EBIDTA: $125.09 million
  • Net Margins: -16.93%
  • Return on Equity: -7.49%
  • Return on Assets: -1.73%
  • Debt-to-Equity Ratio: 2.46%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.16%
  • Average Volume: 1.62 million shs.
  • Beta: 1.33
  • Short Ratio: 8.14

Frequently Asked Questions for Depomed (NASDAQ:DEPO)

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.18. The firm earned $95 million during the quarter, compared to analysts' expectations of $99.48 million. Depomed had a negative return on equity of 7.49% and a negative net margin of 16.93%. The company's quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.04 earnings per share. View Depomed's Earnings History.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

8 analysts have issued 1 year target prices for Depomed's shares. Their predictions range from $10.00 to $26.00. On average, they anticipate Depomed's stock price to reach $17.00 in the next year. View Analyst Ratings for Depomed.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
  • 3. Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)

Are investors shorting Depomed?

Depomed saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 12,563,978 shares, a decline of 7.7% from the March 31st total of 13,612,462 shares. Based on an average trading volume of 2,280,917 shares, the short-interest ratio is presently 5.5 days. Approximately 20.5% of the company's stock are short sold.

Who are some of Depomed's key competitors?

Who owns Depomed stock?

Depomed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.72%), State Street Corp (3.82%), Naya Capital Management UK Ltd. (3.15%), Litespeed Management L.L.C. (2.95%), Dimensional Fund Advisors LP (2.00%) and Deltec Asset Management LLC (1.73%). Company insiders that own Depomed stock include August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Who sold Depomed stock? Who is selling Depomed stock?

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Naya Capital Management UK Ltd., Schwab Charles Investment Management Inc., Oxford Asset Management, Kennedy Capital Management Inc., Dimensional Fund Advisors LP, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Alliancebernstein L.P. and Russell Investments Group Ltd.. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas. View Insider Buying and Selling for Depomed.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was bought by a variety of institutional investors in the last quarter, including Litespeed Management L.L.C., Vanguard Group Inc., Capital Fund Management S.A., Renaissance Technologies LLC, Gabelli Funds LLC, Cornerstone Capital Management Holdings LLC., Hussman Strategic Advisors Inc. and State Street Corp. View Insider Buying and Selling for Depomed.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Depomed stock cost?

One share of Depomed stock can currently be purchased for approximately $10.20.

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $17.00 (66.67% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017MizuhoLower Price TargetNeutral$13.00 -> $11.00MediumView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
5/10/2017Royal Bank of CanadaLower Price TargetSector Perform$19.00 -> $13.00LowView Rating Details
5/10/2017Piper Jaffray CompaniesUpgradeUnderweight -> Neutral$11.00 -> $10.00HighView Rating Details
4/11/2017Janney Montgomery ScottReiterated RatingBuy$26.00LowView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Depomed (NASDAQ:DEPO)
Earnings by Quarter for Depomed (NASDAQ:DEPO)
Earnings History by Quarter for Depomed (NASDAQ:DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)


Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 5.12%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
DateHeadline logoDepomed Inc (DEPO) Stock Rating Reaffirmed by Mizuho - May 25 at 9:52 PM logoShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development - May 24 at 12:36 PM logoBRIEF-Depomed announces corporate governance updates - May 22 at 11:59 AM logoDepomed Announces Corporate Governance Updates - May 22 at 11:59 AM logoDepomed Inc (DEPO) Given a $14.00 Price Target at Cantor Fitzgerald - May 15 at 3:15 PM logoDepomed Inc (DEPO) Upgraded to Neutral by Piper Jaffray Companies - May 14 at 6:28 PM logo Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $110.54 Million - May 14 at 8:50 AM logoZacks: Analysts Anticipate Depomed Inc (DEPO) to Announce -$0.35 Earnings Per Share - May 12 at 8:28 PM logoToday's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed - May 12 at 3:24 PM logoDepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise - - May 11 at 5:21 PM logoDepomed Focuses on Flagship Drug Rather Than M&A: CEO - May 10 at 9:55 PM logoDepomed's (DEPO) "Sector Perform" Rating Reiterated at Royal Bank of Canada - May 10 at 6:28 PM logoBRIEF-Depomed reports Q1 adjusted non-GAAP earnings $0.07/shr - May 10 at 4:51 PM logoDepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise - May 10 at 4:51 PM logoBiotech Movers: Depomed Shares Tank After Losses Get Even Worse - May 10 at 4:51 PM logoDepomed Q1 top line down 14%; loss widens; guidance lowered; shares sink 16% premarket - May 10 at 8:56 AM logoEdited Transcript of DEPO earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 5:28 AM logoDepomed Inc (DEPO) Releases Earnings Results, Misses Estimates By $0.06 EPS - May 9 at 10:44 PM logoDepomed reports 1Q loss - May 9 at 6:45 PM logoInvestor Network: Depomed, Inc. to Host Earnings Call - May 9 at 4:41 PM logoDepomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value - May 9 at 4:41 PM logoDepomed shares down 13% after earnings miss - May 9 at 4:41 PM logoAs Sohn Opens, Here's How Hedge Fund Titans Fared With Picks - May 8 at 4:30 PM logoDepomed Inc (DEPO) Receives Consensus Recommendation of "Hold" from Analysts - May 8 at 1:26 PM logoWhat will be the hot pick from this year’s Sohn hedge-fund conference? - May 5 at 4:54 PM logoDepomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 - Yahoo Finance - May 3 at 8:44 AM logoPositive Media Coverage Very Likely to Affect Depomed (DEPO) Share Price - May 3 at 12:00 AM logoDepomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 - May 2 at 7:34 PM logoRoyal Bank of Canada Reiterates Neutral Rating for Depomed Inc (DEPO) - May 2 at 3:02 PM logoDepomed Inc (DEPO) Stock Rating Lowered by TheStreet - May 1 at 6:42 PM logoDepomed Inc (DEPO) Short Interest Update - April 28 at 10:54 AM logoDepomed (DEPO) Receiving Somewhat Positive Press Coverage, Study Shows - April 27 at 10:40 PM logoDepomed Inc (DEPO) Expected to Post Quarterly Sales of $101.35 Million - April 26 at 2:22 PM logoDepomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration - April 25 at 11:51 AM logoDepomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration - April 25 at 8:19 AM logoDepomed (DEPO) Receives News Impact Score of 0.44 - April 24 at 3:48 PM logo-$0.23 Earnings Per Share Expected for Depomed Inc (DEPO) This Quarter - April 24 at 11:39 AM logoDepomed (DEPO) Earning Somewhat Favorable Press Coverage, Study Shows - April 21 at 6:41 PM logoDepomed Inc (DEPO) Receives "Buy" Rating from Janney Montgomery Scott - April 14 at 5:27 PM logoDepomed (DEPO) Given Media Impact Rating of 0.54 - April 14 at 9:48 AM logoWhich Drugmakers Will Rock The Sector In Q1? - April 13 at 9:43 PM logoSTRATA Skin Sciences and Depomed Recover from Wednesday's ... - Yahoo Finance - April 11 at 4:31 PM logoDepomed Inc (DEPO) Receives Average Recommendation of "Hold" from Analysts - April 11 at 12:48 PM logoSTRATA Skin Sciences and Depomed Recover from Wednesday's FDA Opioid Shockwave - April 10 at 11:58 AM logoDepomed Announces Prepayment of $100 Million of Secured Debt Facility - April 7 at 9:24 AM logoDepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control - April 7 at 9:24 AM logoDepomed pays down debt $100M, to refi the remainder - April 4 at 12:27 PM logoRoyal Bank of Canada Trims Depomed Inc (DEPO) Target Price to $19.00 - April 4 at 9:14 AM logoDepomed Inc (DEPO) Given a $22.00 Price Target at Royal Bank of Canada - April 1 at 10:18 PM logoDepomed Inc. (DEPO) - March 31 at 9:52 PM



Depomed (DEPO) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff